Skip to content
Research Article Open access CC BY 4.0

Therapeutic Arsenal against Leishmaniases: A Review

Janaína B. de Menezes, Tamires A. da Silva, Luciano A. M. Grillo, Camila B. Dornelas

International Journal of TROPICAL DISEASE & Health · pp. 101–122 · Published 13 Nov 2014

10.9734/IJTDH/2015/13391

Abstract

Leishmaniases are included in the group of reemerging neglected tropical diseases caused by flagellated parasites of the Leishmania genus. WHO recommends the use of chemotherapy as the main control measure for all the types of the disease. Antimonials are the first drug of choice, but they can be replaced by amphotericin B, mitelfosine, paromomycin and pentamidine isethionate, or combinations. Generally, all the medicines that contain these drugs have several drawbacks. In view of this, chemotherapy for Leishmaniasis is increasingly the object of study, searching for safer or more effective drugs or new drug delivery vehicles, where nanotechnology is crucial. Thus, the purpose of this review is to present the therapeutic arsenal available in the market and that has been investigated for this application.

Neglected tropical diseases (NTD) Leishmaniasis chemotherapy leishmanicidal nanotechnology

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.